Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (1379)	3/16/2000 9:35:00 AM
From: nigel bates	Read Replies (1) \| Respond to of 3202

Bought back in today, as there is a serious danger that people might understand that the Clinton/Blair panic is more hype than reality. nig

To: LLCF who wrote (1379)	3/20/2000 8:42:00 AM
From: Lighthouse	Read Replies (1) \| Respond to of 3202

Here was the first bit: Quote \| Real-Time Quote NEW \| Charts \| Real-Time Charts NEW \| News \| Financials \| Discussion \| Earnings Est. \| Profile \| SEC \| Hist. Prices \| Industry Grp. \| Broker Research \| DSP/DRIP \| trade at ndb.com INCY : INCYTE PHARMACEUTICALS (NASDAQ) All Headlines Incyte Announces Increase in Size and Completion of Convertible Note Offering PALO ALTO, Calif., Feb. 15 /PRNewswire/ -- Incyte Pharmaceuticals, Inc. (Nasdaq: INCY) announced today that its recent private placement of 5.5% Convertible Subordinated Notes due 2007 has been increased by $50 million to a total of $200 million principal amount of Notes. The initial purchasers exercised their option to purchase the additional $50 million of Notes, and the offering has been completed. The Notes are convertible into Incyte common stock at an initial conversion price of approximately $134.84 per share. The second bit was the private placement of 2,000,000 shares at $211 oer share.